Clinical Trials
8
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2007
Completed
6
75.0%
Recruiting
2
25.0%
No approval data available
- Nykode Therapeutics showcased its proprietary AI and machine learning platform for multi-antigen immunotherapy optimization at the BioPharma Drug Discovery Nexus conference in Zurich. - The company's lead asset abi-suva demonstrated a 39% objective response rate when combined with KEYTRUDA, compared to 19% for KEYTRUDA alone in the VB-C-03 trial. - Nykode dosed the first patient in its phase II Abili-T trial for HPV+ head and neck cancer in May 2026, with interim analysis expected in 2027. - The company maintains a strong financial position with $51.3 million in cash and a runway extending into 2028, potentially 2029 pending tax case outcomes.
- Epitopea has appointed key executives including Siri Brinchmann-Hansen Torhaug as Head of Oncology Development and Gertrud Koefoed Rasmussen as Head of Development Operations to accelerate clinical development of its CryptiVax™ RNA-based immunotherapies. - The company expanded its research capabilities with the addition of Dr. Theres Oakes as Director of Translational Sciences and Dr. Lisa Smith as Director of Research to support the transition from preclinical to clinical stages. - Epitopea's proprietary CryptoMap™ platform identifies novel Cryptigen™ tumor-specific antigens hidden within cancer's "junk" DNA, targeting a new class of broadly shared antigens across multiple patients with the same tumor type. - The leadership expansion represents a significant milestone in advancing the company's off-the-shelf RNA-based immunotherapies for hard-to-treat cancers into clinical trials.
- Nykode Therapeutics has presented new clinical data at ASCO 2025 for two cancer immunotherapy candidates, VB10.16 and VB10.NEO, both showing robust immune responses when combined with atezolizumab. - VB10.16 demonstrated durable clinical responses in HPV16-positive cervical cancer patients, with stronger T cell responses associated with reduced systemic immunosuppression during treatment. - VB10.NEO, a personalized cancer neoantigen vaccine, induced neoantigen-specific immune responses in 100% of heavily pretreated solid tumor patients, with de novo responses in 85% and durable T cell clone expansion in 82%.
- Personalized cancer vaccines are emerging as a transformative approach in oncology, with BioNTech, Moderna, and myNEO Therapeutics leading development using mRNA technology refined during the COVID-19 pandemic. - The KEYNOTE-942 study demonstrated significant clinical benefit when combining Moderna's mRNA-4157 with Keytruda in melanoma patients, achieving a 74.8% recurrence-free survival rate at 2.5 years versus 55.6% for Keytruda alone. - Despite promising results, manufacturing challenges persist with production costs exceeding $100,000 per patient, though advancements in automation and AI-driven technologies are expected to reduce costs and increase accessibility.
